- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00051051
A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer
A Phase II, Randomized, Open-Label Study of Single Agent CI-1033 in Patients With Metastatic Breast Cancer
연구 개요
연구 유형
등록
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Montgomery, Alabama, 미국, 36106
- Pfizer Investigational Site
-
-
California
-
Arroyo Grande, California, 미국, 93420
- Pfizer Investigational Site
-
Montebello, California, 미국, 90640
- Pfizer Investigational Site
-
San Francisco, California, 미국, 94115
- Pfizer Investigational Site
-
-
Colorado
-
Aurora, Colorado, 미국, 80010
- Pfizer Investigational Site
-
-
Florida
-
Aventura, Florida, 미국, 33180
- Pfizer Investigational Site
-
Miami Beach, Florida, 미국, 33140
- Pfizer Investigational Site
-
Plantation, Florida, 미국, 33324
- Pfizer Investigational Site
-
-
Illinois
-
Chicago, Illinois, 미국, 60637-1470
- Pfizer Investigational Site
-
Maywood, Illinois, 미국, 60153
- Pfizer Investigational Site
-
-
Kansas
-
Kansas City, Kansas, 미국, 66112
- Pfizer Investigational Site
-
Lenexa, Kansas, 미국, 66214
- Pfizer Investigational Site
-
Overland Park, Kansas, 미국, 66210
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Pfizer Investigational Site
-
Boston, Massachusetts, 미국, 02115
- Pfizer Investigational Site
-
Boston, Massachusetts, 미국, 02215
- Pfizer Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109-0922
- Pfizer Investigational Site
-
Brownstown, Michigan, 미국, 48183
- Pfizer Investigational Site
-
Dearborn, Michigan, 미국, 48126
- Pfizer Investigational Site
-
Detroit, Michigan, 미국, 48202
- Pfizer Investigational Site
-
West Bloomfield, Michigan, 미국, 48322
- Pfizer Investigational Site
-
-
Missouri
-
Kansas City, Missouri, 미국, 64111
- Pfizer Investigational Site
-
Kansas City, Missouri, 미국, 64131
- Pfizer Investigational Site
-
Kansas City, Missouri, 미국, 64154
- Pfizer Investigational Site
-
Lee's Summit, Missouri, 미국, 64064
- Pfizer Investigational Site
-
-
New York
-
Bronx, New York, 미국, 10461
- Pfizer Investigational Site
-
Bronx, New York, 미국, 10467
- Pfizer Investigational Site
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106
- Pfizer Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- Pfizer Investigational Site
-
-
Tennessee
-
Gallatin, Tennessee, 미국, 37066
- Pfizer Investigational Site
-
Hermitage, Tennessee, 미국, 37076
- Pfizer Investigational Site
-
Lebanon, Tennessee, 미국, 37087
- Pfizer Investigational Site
-
Murfreesboro, Tennessee, 미국, 37130
- Pfizer Investigational Site
-
Nashville, Tennessee, 미국, 37203
- Pfizer Investigational Site
-
Nashville, Tennessee, 미국, 37205
- Pfizer Investigational Site
-
Nashville, Tennessee, 미국, 37207
- Pfizer Investigational Site
-
Nashville, Tennessee, 미국, 37211
- Pfizer Investigational Site
-
-
Texas
-
Dallas, Texas, 미국, 75246
- Pfizer Investigational Site
-
Houston, Texas, 미국, 77030
- Pfizer Investigational Site
-
San Antonio, Texas, 미국, 78229
- Pfizer Investigational Site
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112
- Pfizer Investigational Site
-
-
Washington
-
Walla Walla, Washington, 미국, 99362
- Pfizer Investigational Site
-
-
-
-
-
Brussels, 벨기에, 1070
- Pfizer Investigational Site
-
Brussels, 벨기에, 1000
- Pfizer Investigational Site
-
Leuven, 벨기에, 3000
- Pfizer Investigational Site
-
-
-
-
-
Stockholm, 스웨덴, 118 83
- Pfizer Investigational Site
-
Stockholm, 스웨덴, 17176
- Pfizer Investigational Site
-
-
-
-
-
Madrid, 스페인, 28041
- Pfizer Investigational Site
-
Madrid, 스페인, 28040
- Pfizer Investigational Site
-
-
-
-
-
Dublin 8, 아일랜드
- Pfizer Investigational Site
-
Galway, 아일랜드
- Pfizer Investigational Site
-
-
-
-
-
Glasgow, 영국, G11 6NT
- Pfizer Investigational Site
-
London, 영국, SE1 9RT
- Pfizer Investigational Site
-
London, 영국, SW3 6JJ
- Pfizer Investigational Site
-
-
Surrey
-
Sutton, Surrey, 영국, SM2 5PT
- Pfizer Investigational Site
-
-
-
-
-
Bologna, 이탈리아, 40139
- Pfizer Investigational Site
-
Forli', 이탈리아, 47100
- Pfizer Investigational Site
-
Modena, 이탈리아, 41100
- Pfizer Investigational Site
-
Roma, 이탈리아, 00144
- Pfizer Investigational Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V5Z 4E6
- Pfizer Investigational Site
-
-
Ontario
-
Hamilton, Ontario, 캐나다, L8V 5C2
- Pfizer Investigational Site
-
-
Quebec
-
Chicoutimi, Quebec, 캐나다, G7H 5H6
- Pfizer Investigational Site
-
Montreal, Quebec, 캐나다, H2L 4M1
- Pfizer Investigational Site
-
-
-
-
-
Avignon Cedex 2, 프랑스, 84082
- Pfizer Investigational Site
-
Paris Cedex 05, 프랑스, 75248
- Pfizer Investigational Site
-
Paris Cedex 13, 프랑스, 75651
- Pfizer Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Female, at least 18 years of age
- Histologically confirmed diagnosis of breast cancer
- Metastatic (Stage IV) disease
- Progressive or recurrent disease following the most recent therapy
- No more than 2 different, prior cytotoxic chemotherapy regimens for metastatic disease
- At least one measurable target lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) that has not been irradiated
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, determined within 2 weeks prior to randomization
- Estimated life expectancy of > 12 weeks
- Capable of giving written informed consent
- Capable of swallowing intact CI-1033 capsules
- Capable of understanding and adhering to the protocol requirements
- No prior exposure to CI-1033 or other agents that target the erbB receptor family (such as Herceptin, Iressa, Tarceva, IMC-C225, and EKB-569)
- No known hypersensitivity reaction to tyrosine kinase inhibitors
- Adequate liver, renal, or bone marrow function determined within 2 weeks prior to randomization
- No cytotoxic chemotherapy within 3 weeks prior to baseline disease assessments (6 weeks for nitrosoureas or mitomycin)
- No immunotherapy (including Herceptin) or other biologic therapy within 2 weeks prior to baseline disease assessments
- No hormone therapy (including hormone replacement therapy) within 4 weeks prior to baseline disease assessments (6 weeks for megestrol acetate)
- Patients must have recovered from the acute effects of any radiation therapy or surgery
- No treatment with any other investigational therapy within 4 weeks prior to baseline disease assessments
- No history of any cancer other than the present condition (except nonmelanoma skin cancer or carcinoma in situ of the cervix) within the last 5 years
- No patients with untreated brain metastases or patients that have not recovered from treatment for brain metastases
- No known malabsorption syndrome or other condition that may impair absorption of study medication
- No comorbidity or condition which compromises compliance with this protocol as judged by the investigator or that would significantly complicate interpretation of the safety profile of CI-1033
- No patients having reproductive potential who are not using a method of birth control or who are pregnant or breastfeeding or have a positive pregnancy test during baseline
Exclusion Criteria:
Prior exposure to CI-1033 or other agents that target the erbB receptor family; cytotoxic chemotherapy within 3 weeks prior to baseline disease assessments (6 weeks for nitrosoureas or mitomycin); immunotherapy (including Herceptin) or other biologic therapy within 2 weeks prior to baseline disease assessments; hormone therapy (including hormone replacement therapy) within 4 weeks prior to baseline disease assessments; 6 weeks for megestrol acetate (to exclude the possibility of a hormone-withdrawal response); patients with untreated brain metastases.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
|---|
|
The primary objective is to assess the antitumor activity of CI 1033 in patients with metastatic breast cancer.
|
2차 결과 측정
결과 측정 |
|---|
|
Secondary objectives include an assessment of safety and patient reported outcomes (eg, quality of life [QOL])
|
|
correlations between erbB expression and efficacy
|
|
exploratory analyses of soluble erbB-2 or other biomarkers
|
|
exploratory questions to measure the patient-reported impact of diarrhea and skin reactions will also be assessed
|
공동 작업자 및 조사자
스폰서
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 1033-011
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .